Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Prostatic Neoplasms 3Prostate Cancer Metastatic 2Myasthenia Gravis 2Multiple Myeloma 2Waldenstrom Macroglobulinemia 1Subcutaneous panniculitis-like T-cell lymphoma 1Skin Neoplasms 1Prostatic Neoplasms, Castration-Resistant 1Pneumonia 1Pituitary Neoplasms 1Neoplasms, Plasma Cell 1Neoplasm, Residual 1Metastatic Castration-resistant Prostate Cancer 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Lung Neoplasms 1Lung Diseases, Interstitial 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immunoblastic Lymphadenopathy 1Enteropathy-Associated T-Cell Lymphoma 1Dementia 1Craniopharyngioma 1Cognitive Dysfunction 1Autoimmune Diseases 1Arthritis, Rheumatoid 1Adrenal Insufficiency 1

Interventions

Vincristine 3Methotrexate 3Mercaptopurine 3Etoposide 3Daunorubicin 3Cytarabine 3Cyclophosphamide 3Asparaginase 3Vindesine 2Thioguanine 2Teniposide 2Stem Cell Transplantation 2Prednisolone 2Granulocyte Colony-Stimulating Factor 2Doxorubicin 2Dexamethasone 2pegaspargase 1fludarabine 1etoposide phosphate 1blinatumomab 1aldesleukin 1Rituximab 1Prednisone 1Pirinitramide 1Morphine 1Interleukin-2 1Idarubicin 1Histamine 1Cladribine 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Neoplasm, Residual × Prednisone × Clear all
NCT00526175 2016-01-20

LAL-BR/2001: Study Treatment to Low Risk ALL

PETHEMA Foundation

Phase 4 Completed
150 enrolled
LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡